Abstract:This narrative review explores the physiology and evidence-based management of patients with severe acute respiratory distress syndrome (ARDS) and refractory hypoxemia, with a focus on mechanical ventilation, adjunctive therapies, and veno-venous extracorporeal membrane oxygenation (V-V ECMO). Severe ARDS cases increased dramatically worldwide during the Covid-19 pandemic and carry a high mortality. The mainstay of treatment to improve survival and ventilator-free days is proning, conservative fluid management, and lung protective ventilation. Ventilator settings should be individualized when possible to improve patient-ventilator synchrony and reduce ventilator-induced lung injury (VILI). Positive end-expiratory pressure can be individualized by titrating to best respiratory system compliance, or by using advanced methods, such as electrical impedance tomography or esophageal manometry. Adjustments to mitigate high driving pressure and mechanical power, two possible drivers of VILI, may be further beneficial. In patients with refractory hypoxemia, salvage modes of ventilation such as high frequency oscillatory ventilation and airway pressure release ventilation are additional options that may be appropriate in select patients. Adjunctive therapies also may be applied judiciously, such as recruitment maneuvers, inhaled pulmonary vasodilators, neuromuscular blockers, or glucocorticoids, and may improve oxygenation, but do not clearly reduce mortality. In select, refractory cases, the addition of V-V ECMO improves gas exchange and modestly improves survival by allowing for lung rest. In addition to VILI, patients with severe ARDS are at risk for complications including acute cor pulmonale, physical debility, and neurocognitive deficits. Even among the most severe cases, ARDS is a heterogeneous disease, and future studies are needed to identify ARDS subgroups to individualize therapies and advance care.

Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation

Cellular and molecular mechanisms of ACE2/Ang1-7/Mas in ALI/ARDS

Angiotensin II Type 2 Receptor Inhibits M1 Polarization and Apoptosis of Alveolar Macrophage and Protects Against Mechanical Ventilation-Induced Lung Injury

Renin–Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome

Using the sympathetic system, beta blockers and alpha-2 agonists, to address acute respiratory distress syndrome

Pharmacotherapy of acute respiratory distress syndrome

Application Progress of Mechanical Ventilation in Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

The progress of mechanical ventilation strategy for acute respiratory distress syndrome

Pharmacological inhibition of the ACE/Ang-2/AT1 axis alleviates mechanical ventilation-induced pulmonary fibrosis

Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study

Efficacy and safety of several common drugs in the treatment of acute respiratory distress syndrome: A systematic review and network meta-analysis

Novel Biomarkers for Acute Respiratory Distress Syndrome: Genetics, Epigenetics and Transcriptomics

Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

Management of the acute respiratory distress syndrome

Mechanical ventilation in patients with acute respiratory distress syndrome: current status and future perspectives

Innovations in protective mechanical ventilation for acute respiratory distress syndrome management

Renin in critically ill patients

Ventilator for the Treatment of Acute Respiratory Distress Syndrome

Management of severe acute respiratory distress syndrome: a primer